Catheter Precision Announces Strategic Financing and Aviation Acquisition

Catheter Precision ( (VTAK) ) has issued an announcement.

On March 9, 2026, Catheter Precision entered into a private placement with accredited investors to issue multiple new series of convertible preferred stock, initially raising $1.85 million and potentially up to roughly $39 million through additional tranches. The financing, structured with variable conversion prices tied to future market levels and subject to shareholder approval and SEC registration effectiveness, is aimed at funding general corporate needs, restructuring the legacy catheter business, resolving liabilities, and simplifying the company’s capital structure, though it may lead to significant dilution of existing common shareholders once conversions occur.

In parallel on March 9, 2026, Catheter Precision agreed to acquire 100% of Fly Flyte, Inc. and Ponderosa Air, LLC from Creatd, Inc. for total consideration of about $11.6 million, to be paid via cash, a zero‑coupon promissory note maturing in 2026, and new Series D preferred stock that will be convertible into common shares after shareholder approval. The acquisition, coupled with a registration rights agreement to facilitate resale of shares underlying the new preferred stock, signals a strategic shift as the company uses fresh capital and stock-based consideration to pivot away from its legacy operations and expand into new aviation-related assets, while layering in additional complexity and potential future equity issuance.

The most recent analyst rating on (VTAK) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Catheter Precision stock, see the VTAK Stock Forecast page.

Spark’s Take on VTAK Stock

According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.

The score is primarily weighed down by weak financial performance driven by very large ongoing losses and significant cash burn, despite improving revenue. Technicals add additional pressure as the stock trades below major moving averages with negative MACD. Valuation contributes limited support because losses make P/E less informative and no dividend yield is available.

To see Spark’s full report on VTAK stock, click here.

More about Catheter Precision

Catheter Precision, Inc. is a medical device company with a legacy catheter business focused on medical devices, operating as a public company on the NYSE American. The firm is working to restructure its historical catheter operations, reduce liabilities and operating expenses, and reposition itself with a streamlined capital structure and simplified balance sheet.

Average Trading Volume: 78,834

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.35M

For detailed information about VTAK stock, go to TipRanks’ Stock Analysis page.